Highest-materiality recent filing
Kodiak Q2 net loss $65.6M; DAYBREAK topline due Sept 2026, cash into 2027
Q2 2026 net loss $65.6M ($1.05/sh) vs $54.3M ($1.03/sh) in Q2 2025; SBC $11.6M.
Kodiak Sciences annual meeting elects three directors, approves say-on-pay, ratifies auditor
All three Class II director nominees elected: Bancroft with 38.9M for, Dahiyat with 48.8M, Yang with 49.2M.
Kodiak Sciences reports Q1 net loss $0.94/sh; Zenkuda GLOW2 positive, BLA planned
Cash $169.5M as of March 31, 2026, expected to fund operations into 2027.
Kodiak reports positive Phase 3 GLOW2 data for Zenkuda; plans accelerated BLA
Zenkuda Phase 3 GLOW2: 62.5% vs 3.3% achieved ≥2-step DRSS improvement (p<0.0001).
62.5% of Zenkuda patients achieved ≥2-step DRSS improvement vs 3.3% sham (p<0.0001).
Kodiak Sciences completes $184M public offering of 8M shares at $23/sh
Underwriters exercised in full the option for 1,043,478 additional shares, totaling 8,000,000 shares sold.
Kodiak Sciences Q3 net loss $61.5M ($1.16/share); cash $72M; Phase 3 trials on track
Net loss of $61.5M ($1.16/sh) vs $43.9M ($0.84/sh) in Q3 2024; R&D expenses rose to $50.5M from $31.9M on higher clinical and manufacturing activity.
Kodiak Sciences Q2 net loss $54.3M, cash $104.2M; pipeline milestones on track
Net loss of $54.3M ($1.03/share) vs $45.1M loss a year ago; R&D expenses rose to $42.8M.
Kodiak Sciences stockholders elect directors and ratify auditor at 2025 annual meeting
Elected Richard S. Levy, M.D. (29.2M for, 8.4M withheld) and Robert A. Profusek, J.D. (24.7M for, 12.9M withheld) as Class I directors.
Kodiak Sciences Q1 net loss $57.5M ($1.09/shr), cash $138.9M; pipeline on track for 2026 data
Net loss $57.5M ($1.09/shr) vs $43.0M ($0.82) in Q1 2024; non-cash stock comp $15.9M.
Kodiak Sciences reports Q4 net loss of $44.1M, cash $168.1M; pipeline trials on track
Cash and equivalents $168.1M at Dec 31, 2024; expected to fund operations into 2026.
Kodiak Sciences Q3 net loss $43.9M, cash $197.9M; provides pipeline updates
Net loss of $43.9M ($0.84/sh) vs $50.0M ($0.95/sh) in Q3 2023; cash $197.9M expected to fund operations into 2026.
Kodiak Sciences Q2 net loss $45.1M, cash $219.2M; three Phase trials enrolling
Net loss $45.1M ($0.86/sh) vs $80.2M ($1.53/sh) in Q2 2023; R&D expense down 52% to $32.5M.
Kodiak Sciences annual meeting results: Felix Baker receives ~32% withheld votes
Felix J. Baker re-elected with 27,555,597 for, 13,043,671 withheld (~32% of votes cast against).
Kodiak Sciences Q1 net loss $43M, cash $245.9M; advances tarcocimab and KSI-101 trials
Net loss of $43.0M ($0.82 per share) vs $70.8M ($1.35) in Q1 2023; includes $18.4M stock-based compensation.
Kodiak Sciences reports Q4 net loss of $59.5M; outlines Phase 3 plans for tarcocimab and KSI-501
Q4 2023 net loss $59.5M ($1.13/share) vs $70.4M ($1.35/share) in Q4 2022; R&D expenses fell to $46.6M.
Kodiak Sciences Q3 net loss $50M; GLOW study shows tarcocimab 29-fold improvement
Net loss $50.0M ($0.95/shr) vs $77.0M ($1.47) in Q3 2022; cash $345.7M.
Kodiak Phase 3 GLOW NPDR study meets primary endpoint; plans to resume tarcocimab
GLOW met primary endpoint: 41.1% vs 1.4% achieved >=2-step DRSS improvement (p<0.0001).
Resignation as Chief Medical Officer and Chief Development Officer effective August 25, 2023.
Kodiak Sciences Q2 net loss $80.2M; winds down tarcocimab after Phase 3 DME miss
Q2 2023 net loss $80.2M ($1.53/sh) vs $90.6M ($1.74/sh) in Q2 2022.
Cash and equivalents $379M as of June 30, 2023 (unaudited).
Elected Charles A. Bancroft, Bassil I. Dahiyat, and Taiyin Yang as Class II directors with >77% votes for each.
Kodiak Sciences Q1 2023 net loss $70.8M; four Phase 3 readouts expected in Q3 2023
Cash position $421.2M; net loss $70.8M ($1.35/share) vs $95.7M ($1.83/share) Q1 2022.
Kodiak Sciences Q4 net loss $70.4M ($1.35/sh); cash $478.9M; tarcocimab data Q3 2023
Cash, equivalents and marketable securities totaled $478.9M at Dec 31, 2022.
Kodiak Sciences Q3 net loss $77M; cash $537M; Ph3 trials on track for 2023 readouts
Net loss of $77.0M ($1.47/sh) vs $67.5M ($1.30) in Q3 2021; increase driven by stock-based compensation.
Kodiak Sciences Q2 net loss $90.6M; BEACON Phase 3 RVO study meets endpoint
Net loss of $90.6M ($1.74/share) vs $55.9M ($1.08/share) in Q2 2021 driven by higher R&D and stock-based comp.
Kodiak Sciences: BEACON Phase 3 tarcocimab meets primary endpoint in retinal vein occlusion
BEACON Phase 3 randomized 568 RVO patients to tarcocimab 5 mg q8w after 2 monthly loads vs aflibercept 2 mg q4w.
Kodiak Sciences reports 2022 annual meeting voting results; all proposals pass
42,377,902 shares (81.6% of eligible) present at June 7, 2022 annual meeting.
Kodiak Sciences Q1 net loss $95.7M ($1.83/share); updates KSI-301 program after Ph2b/3 miss
Net loss $95.7M ($1.83/share) vs $50.4M ($0.98/share) in Q1 2021.
Kodiak Sciences Q4 net loss $93.2M; wet AMD pivotal trial misses primary endpoint
Phase 2b/3 KSI-301 study in wet AMD did not meet non-inferiority vs aflibercept for extended dosing.
Kodiak Sciences: KSI-301 fails primary endpoint in wet AMD Phase 2b/3 trial
Primary endpoint not met: KSI-301 failed to show non-inferior visual acuity gains vs aflibercept in wet AMD.
Kodiak Q3 net loss $67.5M ($1.30/shr); cash $799M; pipeline on track for 2022 readouts
Net loss widened to $67.5M ($1.30/shr) from $36.1M ($0.80/shr) in Q3 2020.
Kodiak shareholders approve 5.5M-share long-term incentive plan for executives
Shareholders voted 77% in favor (Bylaws Standard) to approve the 2021 Long-Term Performance Incentive Plan.
NEOs and eligible employees may forgo up to 75% of annual equity awards for 7 years in exchange for one-time performance stock options.
Kodiak Sciences Q2 net loss widens to $55.9M; KSI-301 trials on track for data in early 2022
Net loss of $55.9M ($1.08/share) vs $26.0M ($0.58) in Q2 2020; R&D expenses rose to $45.4M.
Kodiak Sciences avoids $125M royalty-draw; reduces royalty cap to $450M
Company and BBA agreed not to fund second $125M tranche of royalty financing agreement.
On August 16, 2023, Jason Ehrlich, M.D., Ph.D., informed the Company of his resignation as Chief Medical Officer and Chief Development Officer of the Company, effective August 25, 2023.
Max materiality 0.90 · Median 0.65 · Most common event earnings